Evidence map›Paper›PMID 36720285›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2023

Sex-based differences of antioxidant enzyme nanoparticle effects following traumatic brain injury.

Aria W Tarudji, Hunter A Miller, Evan T Curtis, Christopher L Porter, Gary L Madsen, Forrest M Kievit

Open access · greenAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Neurotrauma reports · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Aria W TarudjiDepartment of Biological Systems Engineering, University of Nebraska - Lincoln, 262 Morrison Center, Lincoln, NE 68583, USA.
Hunter A MillerDepartment of Biological Systems Engineering, University of Nebraska - Lincoln, 262 Morrison Center, Lincoln, NE 68583, USA; ProTransit Nanotherapy, 16514L St., Omaha, NE 68135, USA.
Evan T CurtisDepartment of Biological Systems Engineering, University of Nebraska - Lincoln, 262 Morrison Center, Lincoln, NE 68583, USA.
Christopher L PorterProTransit Nanotherapy, 16514L St., Omaha, NE 68135, USA.
Gary L MadsenProTransit Nanotherapy, 16514L St., Omaha, NE 68135, USA.
Forrest M KievitDepartment of Biological Systems Engineering, University of Nebraska - Lincoln, 262 Morrison Center, Lincoln, NE 68583, USA. Electronic address: fkievit2@unl.edu.
University of Nebraska–Lincoln · US

Funding

Nanoparticle-mediated reduction of oxidative stress for the treatment of traumatic brain injuryR01NS109488 · NINDS · UNIVERSITY OF NEBRASKA LINCOLN · PI KIEVIT, FORREST M · 2019 to 2023
$2.2M
Antioxidant enzyme-loaded Pro-NP for treatment of TBI.R41NS119082 · NINDS · PROTRANSIT NANOTHERAPY, LLC · PI KIEVIT, FORREST M, MADSEN, GARY LEONARD · 2020 to 2020
$260k
NINDS NIH HHS R01 NS109488NINDS NIH HHS R41 NS119082
6 · The paper itself

Abstract

Following traumatic brain injury (TBI), reactive oxygen species (ROS) are released in excess, causing oxidative stress, carbonyl stress, and cell death, which induce the additional release of ROS. The limited accumulation and retention of small molecule antioxidants commonly used in clinical trials likely limit the target engagement and therapeutic effect in reducing secondary injury. Small molecule drugs also need to be administered every several hours to maintain bioavailability in the brain. Therefore, there is a need for a burst and sustained release system with high accumulation and retention in the injured brain. Here, we utilized Pro-NP™ with a size of 200 nm, which was designed to have a burst and sustained release of encapsulated antioxidants, Cu/Zn superoxide dismutase (SOD1) and catalase (CAT), to scavenge ROS for >24 h post-injection. Here, we utilized a controlled cortical impact (CCI) mouse model of TBI and found the accumulation of Pro-NP™ in the brain lesion was highest when injected immediately after injury, with a reduction in the accumulation with delayed administration of 1 h or more post-injury. Pro-NP™ treatment with 9000 U/kg SOD1 and 9800 U/kg CAT gave the highest reduction in ROS in both male and female mice. We found that Pro-NP™ treatment was effective in reducing carbonyl stress and necrosis at 1 d post-injury in the contralateral hemisphere in male mice, which showed a similar trend to untreated female mice. Although we found that male and female mice similarly benefit from Pro-NP™ treatment in reducing ROS levels 4 h post-injury, Pro-NP™ treatment did not significantly affect markers of post-traumatic oxidative stress in female CCI mice as compared to male CCI mice. These findings of protection by Pro-NP™ in male mice did not extend to 7 d post-injury, which suggests subsequent treatments with Pro-NP™ may be needed to afford protection into the chronic phase of injury. Overall, these different treatment effects of Pro-NP™ between male and female mice suggest important sex-based differences in response to antioxidant nanoparticle delivery and that there may exist a maximal benefit from local antioxidant activity in injured brain.

Indexed as

Brain Injuries, TraumaticNanoparticlesAnimalsAntioxidantsDelayed-Action PreparationsFemaleMaleMiceOxidative StressReactive Oxygen SpeciesSuperoxide Dismutase-1AntioxidantsDelayed-Action PreparationsReactive Oxygen SpeciesSuperoxide Dismutase-1Carbonyl stressLipid peroxidation productsPLGA nanoparticlesReactive oxygen speciesTraumatic brain injuryTreatment window

Identifiers

PMID36720285
PMCPMC10006352
OpenAlexW4318755576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.